Dysferlin-Peptides Reallocate Mutated Dysferlin Thereby Restoring Function

Verena Schoewel1, Andreas Marg1, Severine Kunz1, Tim Overkamp2, Romy Siegert Carrazedo1, Ute Zacharias1, Peter T. Daniel2, Simone Spuler1*

1 Muscle Research Unit, Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and Max Delbrück Center for Molecular Medicine, Berlin, Germany, 2 Clinical and Molecular Oncology, University Medical Center Charité, Campus Berlin-Buch, Berlin, Germany

Abstract

Mutations in the dysferlin gene cause the most frequent adult-onset limb girdle muscular dystrophy, LGMD2B. There is no therapy. Dysferlin is a membrane protein comprised of seven, beta-sheet enriched, C2 domains and is involved in Ca2+-dependent sarcolemmal repair after minute wounding. On the protein level, point mutations in DYSF lead to misfolding, aggregation within the endoplasmic reticulum, and amyloidogenesis. We aimed to restore functionality by relocating mutant dysferlin. Therefore, we designed short peptides derived from dysferlin itself and labeled them to the cell penetrating peptide TAT. By tracking fluorescently labeled short peptides we show that these dysferlin-peptides localize in the endoplasmic reticulum. There, they are capable of reducing unfolded protein response stress. We demonstrate that the mutant dysferlin regains function in membrane repair in primary human myotubes derived from patients’ myoblasts by the laser wounding assay and a novel technique to investigate membrane repair: the interventional atomic force microscopy. Mutant dysferlin abuts to the sarcolemma after peptide treatment. The peptide-mediated approach has not been taken before in the field of muscular dystrophies. Our results could redirect treatment efforts for this condition.

Introduction

Dysferlin is a type II membrane protein in the ferlin family with a short extracellular 12 amino-acid domain. Dysferlin contains seven C2 domains and is involved in Ca2+-dependent membrane repair after sarcolemmal microinjuries [1,2]. Limb-girdle muscular dystrophy 2B (LGMD2B) is the most prominent dysferlinopathy caused by mutations in the dysferlin (DYSF) gene [3,4]. Young adults are affected and become wheelchair bound within 15 years. Other dysferlinopathies are Miyoshi myopathy, anterior-tibial myopathy, idiopathic hyperCKemia, and rare congenital forms. There is no treatment. DYSF is a large gene with 55 exons encoding a 2080 amino-acid protein. More than 1000 DYSF mutations have been described [5,6]. They are distributed evenly over the entire length of the gene without mutational hotspots. At least a third of the DYSF mutations are missense mutations. We and others have demonstrated that DYSF missense mutations cause dysferlin aggregation and misfolding, amyloid formation, and subsequent degradation by the endoplasmic reticulum-associated protein degradation machinery (ERAD) [7,8,9]. Protein misfolding is the cause of numerous progressive hereditary and acquired diseases including Alzheimer’s dementia, Parkinson’s disease, and cystic fibrosis. Research directed towards protein refolding and prevention of premature degradation in the endoplasmic reticulum (ER) is intensively studied [10,11]. Dysferlinopathy is the first muscular dystrophy where faulty protein aggregation was established. We asked whether mutant dysferlin trapped within the ER could be redirected to the sarcolemma and whether mutant dysferlin would be functional at this site. We selected specifically designed dysferlin-peptides coupled to the cell-penetrating peptide TAT [trans-activator of transcription from human immunodeficiency virus type 1] and demonstrate that these peptides support mutant dysferlin to relocate and to regain proper function.

Results

Dysferlin-peptides Cause DYSF Missense Mutants to Relocate to the Sarcolemma in C2C12 Cells

We selected two defined DYSF missense mutations for our experimental design: DYSF p.G299R and DYSF p.L1341P. The consequences of these mutations at the protein level have been shown previously [6]. Both mutations lead to the absence of dysferlin at the sarcolemma and to protein aggregation within the ER. These variants were cloned into the pcDNA4/TO vector containing the full-length human DYSF cDNA-GFP-tagged. C2C12 murine muscle cells were transfected with wildtype (WT) or mutant dysferlin. Transfection with WT dysferlin resulted in membrane staining (Fig. 1A–C); however, the mutants as expected, aggregated within the cells (Fig. 1D, G). We next explored the effect of peptides specifically designed to resemble the
respective $DYSF$ mutations. We coupled 10mer and 15mer dysferlin-peptides to the human immunodeficiency virus transactivator protein at their N-terminal ends (Table 1 and Fig. S1). Eleven hours after last addition of TAT-labeled dysferlin-peptides to C2C12 cells, we detected dysferlin at sarcolemmal sites. This effect was most efficient when the shortest peptides were used that contained the mutated amino acid (Fig. 1E, H). Longer peptides (15mer) caused a weaker membranous redistribution (Fig. 1I and Fig. S2B); peptides reflecting the wildtype sequence led to a dispersion of otherwise accumulated dysferlin but we were not able to detect dysferlin at the muscle membrane (Fig. 1F and Fig. S2D). All experiments were also performed in C2C12 cells harboring a permanent knockdown of the dysferlin gene (not shown).

Dysferlin-peptides Cause Reallocation of $DYSF$ Missense Mutants in Primary Human myotubes

We next tested whether or not TAT-labeled dysferlin-peptides would elicit an effect on primary human myotubes obtained from patients with $DYSF$ p.G299R and $DYSF$ p.L1341P. Missense mutated dysferlin accumulates within the myotubes (Fig. 2A and D, Fig. S3) and does not localize to the sarcolemma as it can be seen in multinucleated human muscle cells from normal controls (Fig. 2F). Similar to the results seen in C2C12 cells, addition of TAT-labeled specific peptides to dysferlin-deficient human myotubes resulted in translocation of mutant dysferlin to the sarcolemma (Fig. 2B and E, Fig. S3). Again, 10-mer peptides containing the corresponding mutation were most effective. Peptides corresponding to the wildtype sequence or nonsense peptides (Fig. 2C, Fig. S3) did not show these effects on dysferlin localization. Thus, the short peptides derived from mutant dysferlin and coupled to TAT are effective in retargeting dysferlin to the sarcolemma.

Missense Mutant dysferlin is Functional after Reallocation

We next tested the function of mutant dysferlin reallocated with TAT-labeled dysferlin-peptides by two independent methods. First, we performed laser wounding of the sarcolemma in primary human myotubes. Due to the impaired membrane repair ability dysferlin-deficient myofibers show influx of fluorescent dye into the myotube [2]. We adapted the method to primary human myotubes. Because of the smaller size of the myotubes as compared to murine intact muscle fibers the wounding area was only $2.5 \times 2.5 \mu m$. Compared to normal human myotubes (Fig. 3D and E, video S4) dye influx was significantly increased in dysferlin-mutants (Fig. 3A and E, video S1). TAT-labeled dysferlin-peptides harboring the mutation significantly improve the ability of the

![Figure 1. Dysferlin-peptides redirect mutant dysferlin in transfected C2C12 cells.](image-url)
sarcolemma to reseal (Fig. 3C and E; video S3). Non-specific peptides also elicited some effect on membrane resealing; however, this effect did not reach statistical significance (Fig. 3B and E, video S2).

We applied a second method to wound myotubes at the single-cell level. We used atomic force microscopy to induce and visualize membrane wounding and repair in normal and dysferlin-mutant human myotubes. *DYSF* p.L1341P myotubes, untreated and treated with TAT-labeled dysferlin-peptides, were wounded by applying a 2 \( \mu \)m longitudinal cut with a force of 40 nN with a CSC37 cantilever (Fig. 4 and video S5, S6, S7). The size of lesions corresponded to the description of earliest events of membrane disruptions in dysferlinopathies [12]. We detected membrane healing in normal (Fig. 4A–C, video S5) and also in dysferlin-peptide treated LGMD2B (Fig. 4G–I, video S7) myotubes. Untreated dysferlin-mutant myotubes did not exhibit repair (Fig. 4D–F, video S6).

**TAT-labeled Mutant dysferlin-peptides Localize to the ER**

To investigate the mechanism elicited by the dysferlin derived peptides, we monitored their fate after administration to myotubes. Peptide B2, which corresponds to the *DYSF* p.L1341P mutation, was fluorescently labeled with ATTO 495-ME (YGRKKRRQRRR-C(ATTO-495-ME)-LAWGPRNMKS-amid).

### Table 1. Dysferlin-derived peptides.

| Nomenclature | Description | Sequence of TAT-labeled dysferlin-peptides |
|--------------|-------------|--------------------------------------------|
| A1           | 10mer, analogous to wildtype | YGRKKRRQRRR- DALLGEFRMD- amid |
| A2           | 10mer, analogous to mutant   | YGRKKRRQRRR- DALLREFRMD- amid |
| A3           | 15mer, analogous to wildtype | YGRKKRRQRRR- LRTDALLGEFRMDVG- amid |
| A4           | 15mer, analogous to mutant   | YGRKKRRQRRR- LRTDALLREFRMDVG- amid |
| B1           | 10mer, analogous to wildtype | YGRKKRRQRRR- LAWLGNMKMS- amid |
| B2           | 10mer, analogous to mutant   | YGRKKRRQRRR- LAWPGPRNMKS- amid |
| B3           | 15mer, analogous to wildtype | YGRKKRRQRRR- IEILAWGLRNMKSYQ- amid |
| B4           | 15mer, analogous to mutant   | YGRKKRRQRRR- IEILAWPGPRNMKSQY- amid |
| Fluorescent B2 peptide | 10mer, analogous to mutant | YGRKKRRQRRR- C(ATTO-495-ME)-LAWGPRNMKS- amid |

**Figure 2. Dysferlin-peptides redirect mutant dysferlin to the sarcolemma in primary human myotubes.** Primary human myotubes carrying dysferlin missense mutations were treated with the TAT-labeled dysferlin-peptides. Dysferlin was detected by anti-dysferlin ab. Nuclei are stained with Hoechst. Missense mutated dysferlin aggregates within the myotubes (A, D). After treating human myotubes with 10mer peptides (B, E) harboring the missense mutation mutant dysferlin can be localized at sarcolemmal sites whereas nonsense peptides (C) do not elicit this effect. (A–C) Primary human myotubes expressing *DYSF* p.G299R. Experiment performed 9x. (A) No peptides added. (B) Peptide A2 (10-mer) added corresponding to *DYSF* p.G299R. (C) Nonsense peptide added (control). (D–E) Primary human myotubes harboring the dysferlin mutation p.L1341P. Experiment performed 7x. (D) No peptides added. (E) Peptide B2 (10-mer) added corresponding to *DYSF* p.L1341P. (F) Sarcolemmal dysferlin localization in a normal human myotube. Bar: 10 \( \mu \)m. Arrows indicate reallocated dysferlin to sarcolemmal sites.

![Figure 2](https://www.plosone.org/figure/2)

doi:10.1371/journal.pone.0049603.t001

doi:10.1371/journal.pone.0049603.g002

**Figure 2.** Dysferlin-peptides redirect mutant dysferlin to the sarcolemma in primary human myotubes. Primary human myotubes carrying dysferlin missense mutations were treated with the TAT-labeled dysferlin-peptides. Dysferlin was detected by anti-dysferlin ab. Nuclei are stained with Hoechst. Missense mutated dysferlin aggregates within the myotubes (A, D). After treating human myotubes with 10mer peptides (B, E) harboring the missense mutation mutant dysferlin can be localized at sarcolemmal sites whereas nonsense peptides (C) do not elicit this effect. (A–C) Primary human myotubes expressing *DYSF* p.G299R. Experiment performed 9x. (A) No peptides added. (B) Peptide A2 (10-mer) added corresponding to *DYSF* p.G299R. (C) Nonsense peptide added (control). (D–E) Primary human myotubes harboring the dysferlin mutation p.L1341P. Experiment performed 7x. (D) No peptides added. (E) Peptide B2 (10-mer) added corresponding to *DYSF* p.L1341P. (F) Sarcolemmal dysferlin localization in a normal human myotube. Bar: 10 \( \mu \)m. Arrows indicate reallocated dysferlin to sarcolemmal sites.
amid) and continuously tracked within the myotube for 14 hours in a life cell imaging setup. The fluorescent TAT-labeled dysferlin-peptide co-localized with calnexin, a marker of the ER. However, this construct never appeared at the cell membrane (Fig. 5 and video S8). Thus, mutant dysferlin-peptides do not migrate to the sarcolemma, but instead localize to the ER. We explored the possibility that the mutant dysferlin peptide might directly bind dysferlin. We performed protein-binding studies between the recombinant C2E domain of dysferlin that contained the DYSF p.L1341P mutation and the corresponding wildtype or mutant dysferlin peptides by surface plasmon resonance analysis. Binding between peptides and recombinant dysferlin was not observed (Fig. S4).

ER Stress is Reduced by Treating DYSF p.G299R Expressing myotubes with TAT-Labeled Mutant dysferlin-peptides

Protein misfolding may lead to the activation of the unfolded protein response (UPR) and ER stress. Indeed, we found a significant up-regulation of HSP5A mRNA encoding for the ER stress sensor BiP in myotubes harboring the DYSF p.G299R mutation compared to normal controls (Fig. 6A). The immunoglobulin heavy chain binding protein BiP (78 kDa glucose-regulated protein, GRP78, HSPA5) is one of the key representatives of the heat shock protein family hsp 70 and was the first namely identified member of the group of ER chaperones [13]. BiP mainly retains misfolded proteins in the ER [14] and is jointly responsible for transferring misfolded proteins through the ER membranes back to the cytosol. Indeed, a complex of EDEM, ERdj5 and BiP prepares and provides terminally misfolded proteins for proteasomal degradation [15]. In case of accumulation of misfolded proteins in the ER, the HSPA5 gene transcription coding for the protein BiP is up-regulated [16] assigning BiP the role of an ER stress sensor [17,18,19,20]. After treatment with the dysferlin-derived mutant peptides we could detect a down-regulation of BiP mRNA expression as well as a reduction on protein level (Fig. 6B–C, Fig. S5C). Moreover, the relative gene expression of ATF6 is down-regulated after treatment. AFT6 is a key transcription factor which transmits ER stress signals to the nucleus inducing expression of ER stress-response genes [21,22]. In addition, we observed a down-regulation of gene expression of the translation attenuator PERK (EIF2AK3) [23,24] as well as CHOP (DDIT3), which induces ER stress mediated apoptosis [25,26,27] (Fig. S5). Thus, specific peptide treatment decreases ER stress in human myotubes expressing DYSF missense mutants.

Discussion

For the first time, a peptide-mediated therapy approach has been taken in the field of muscular dystrophies redirecting a mutant protein to the plasma membrane thereby restoring function. We and others have demonstrated that missense mutated dysferlin causes toxic "gain-of-function" through development of amyloid fibrils and activation of ERAD, as well as loss of function due to failure of dysferlin to anchor into its regular site of action. We show that by adding dysferlin-peptides to the cell-penetrating TAT peptide, constructs can enter the ER, reduce UPR stress and...
release missense mutant dysferlin to the sarcolemma. Moreover, this mutant dysferlin is capable of regaining function. Dysferlinopathy is the only muscular dystrophy so far where a contribution of protein misfolding to disease pathology has been described. However, in other muscle disorders like myofibrillar myopathies, inclusion body myopathies, nemalin myopathies, and FHL-1 mutation-associated muscle disorders protein misfolding has been implied. All these diseases could be candidates that might benefit from rectifying faulty protein aggregation [28,29,30,31].

Due to their low membrane permeability, peptides were long considered to be of minimal therapeutic value. However, the discovery of cell-penetrating peptides (CPPs) that readily cross lipid bilayers has changed this state-of-affairs [32]. These peptides are rich in cationic amino acids and are only about 10 to 16 amino acids long. Today, many different CPPs have been described; TAT, an HIV-peptide, has been the most extensively studied. We demonstrate that uptake into mature myotubes is rapid and efficient (Fig. 5). In vivo, the use of CPP-coupled peptides is more complicated because CPPs lack cell-specificity. Strategies to overcome this problem have been addressed and are based on the physiological or biological features of the targeted organ. To test possibilities specifically targeting skeletal muscle in vivo by CPP-coupled peptides will be both interesting and formidable. The fact that TAT-peptide cargo associates and co-localizes with markers of caveolar uptake, may point towards a way to use muscle-specific caveolae as targets [33,34].

The laser-wounding assay has been used earlier to document the functional role of dysferlin at the cell membrane [2,35]. We also developed an independent wounding assay that allowed us to follow the fate of wounds on a single-cell level [36]. We used atomic force microscopy (AFM) to damage the sarcolemma mechanically and to observe repair kinetics. In atomic force microscopy, a cantilever is used to scan living or solid surfaces on nanoscale; however, interventions at the cell surface are also

Figure 4. Specific peptides cause functional recovery in dysferlin-deficient myotubes: Interventional atomic force microscopy. Mechanical sarcolemmal wounding was induced by atomic force microscopy. In all experiments 2 μm longitudinal lesions were set. Arrows indicate the lesion site. The instrument shown is the cantilever used for membrane wounding. (A–C) Normal human myotube 5, 19 and 30 seconds after wounding. The lesion is hardly detectable and closes rapidly. (D–F) DYSF p.L1341P primary human myotube 6, 20 and 90 sec after wounding. The lesion continuously increases in size. (G–I) DYSF p.L1341P primary human myotube treated with corresponding B2 peptide 6, 22 and 30 seconds after wounding. The lesion disappears rapidly. Scale bar: 10 μm. See also videos S5, S6, S7.

doi:10.1371/journal.pone.0049603.g004
possible as shown here [37,38]. Both assays demonstrate convincing repair of sarcolemmal wounds after treating human myotubes harboring a dysferlin missense mutation with TAT-labeled dysferlin-peptides. In the future, interventional atomic force microscopy may become a valuable tool to dissect sarcolemmal wounding and repair events on molecular level—possibly identifying new mechanisms or proteins in a growing family of molecules associated with membrane repair.

We are confident that dysferlin relocated to the membrane after treatment with TAT-labeled peptides because of restored function. However, sarcolemmal insertion of endogenous mutant dysferlin would only unambiguously be depicted by detecting the extracellular C-terminus on non-permeabilized myotubes. Because the extracellular portion of dysferlin is only 12 amino acids in length the generation of an antibody against this epitope has not been successful.

Many different strategies are currently being considered to deal with protein misfolding in various disorders. Physiological and pharmacological chaperones and small molecules derived from large library screens could be effective. In this context those compounds become of increasing interest which act with higher specificities and therefore with reduced toxicity [39]. In missense-mutated dysferlin we have applied a membrane repair assay, which is labor and time intensive, thus unsuitable for high throughput screen. However, in searching for strategies to intervene with misfolded dysferlin, we identified similarities to approaches used to unfold mutated cystic fibrosis transmembrane regulators (CFTR), the membrane protein affected in cystic fibrosis. In a mechanism called transcomplementation, fragments of the wild-type CFTR protein can rescue the functionally intact chloride channel at the cell membrane. The restoration process was validated in vitro and in cystic fibrosis mice in vivo [40,41]. The mechanism of peptide-mediated relocalization is still unknown. Instead of delivering cDNA vector constructs encoding for truncated proteins to the targeting tissue, here we directly administered the short peptide itself avoiding the need of any viral gene delivery approach. Our results confirm the cellular localization of the peptides in the ER, but in our hands best results were achieved with therapeutic peptides harboring the mutation and not reflecting the wildtype sequence.

Recently, it was shown, that the isolated C2B to C2G domain as well as the transmembrane region of dysferlin are capable of binding to their homologous partners. These interactions form the total dysferlin protein to a homodimer in vivo [42]. We investigated two missense mutations located in different C2 domains of the dysferlin protein structure: the C2B and C2E domain (Fig. S1). Here, we show strong evidence, that the specific peptides reflecting the dysferlin sequence itself allow some dysferlin harboring the amino acid exchange to escape protein accumulation and degradation to fulfill their task at the plasma membrane. This might lead to the hypothesis, that the specific peptides may transiently be capable of stabilizing the missense mutated proteins during folding in the ER. Supportively, the primary up-regulation of the ER stress sensor BiP in human myotubes expressing misfolded dysferlin can be reversed by treatment with dysferlin mutant peptides (Fig. 6). This would be consistent with the reduction of the amount of misfolded proteins within the ER by dysferlin-peptide treatment. Consequentially, gene expression of the ER stress mediator proteins ATF6 and PERK were likewise down-regulated after treatment as well as the expression of CHOP, an inducer of ER stress-mediated apoptosis (Fig. S5). The amelioration of ER stress-induced dysfunction may additively contribute to the restoration of the cellular function. Apparently, the amount of dysferlin at the sarcolemma required for normal

![Figure 5. TAT-labeled dysferlin-peptides in primary human myotubes localize to the ER. Peptide B2 corresponding to DYSF p.L1341P was labeled with ATTO-495-ME fluorescent dye (red) and added to DYSF p.L1341P human myotubes. (A) DYSF p.L1341P human myotube immediately after addition of ATTO-495-ME-peptide B2 to DYSF p.L1341P human myotubes, (B) after 8 minutes and (C) after 4 hours. (D) Immunostain using anti-calnexin ab (blue). Perfect co-localization of ATTO-495-ME-peptide B2 and ER marker calnexin. No dysferlin-peptide detected at the sarcolemma. Bar: 10 μm. See also video S8.](https://doi.org/10.1371/journal.pone.0049603.g005)
sarcromelial wound repair is only around 10% [43], suggesting that a therapeutic approach might even be effective despite an incomplete rescue.

Missense mutated dysferlin has been lately shown to may escape protein degradation by unspecific blocking of the ubiquitin-proteasome system [44]. Bortezomib has been approved for the therapeutically treatment of multiple myeloma and mantle cell lymphoma taking advantage of its primary effect on cells with high proliferation rate and therefore high protein turnover inducing cell cycle arrest and apoptosis [45]. The application regime is limited to the development of adverse events due to the unspecific affection of other organ systems and the overall activation of the unfolded protein response [46,47,48,49,50]. Taking this into account, the long-term treatment of chronic diseases ideally relies on the specific targeting of the particular misfolded candidate protein and the stabilization of cellular homeostasis by reducing ER stress related dysfunction. The dysferlin-derived peptide treatment provides a promising approach to fulfill these criteria. Imaging studies after administration of labeled peptides in an animal model would provide further insights regarding the systemic tissue distribution and functional specificity.

We conclude, that the TAT-labeled dysferlin-specific peptides promote mutant dysferlin to reallocate within the cell and to regain function. The peptides function in the ER by interfering with the accumulation of misfolded dysferlin and thereby reducing ER stress in patients’ myotubes.

**Materials and Methods**

**Ethics Statement: Patients and Patient Material**

Muscle biopsy specimens from patients with LGMD2B (dysferlin mutations) were obtained for diagnostic purposes and from normal controls were obtained during hip surgery (Ethical approval EA1/205/08). All studies were performed according to the declaration of Helsinki and were approved by the local ethical committee (Ethics Committee – Charité, University Medicine Berlin). Written informed consent was obtained from all subjects. The patients with dysferlinopathy were affected by the following dysferlin mutations: homozygous c.4022T>C (patient 1), compound heterozygous c.855+1delG/c.895G>A (patient 2).
Cells and Cell Culture

C2C12 cells were obtained from DSMZ (Braunschweig, Germany). Dysferlin-deficient C2C12 cells were a gift from Dr. Robert Brown (University of Massachusetts School of Medicine, Worcester, USA) [51]. Dysferlin-deficient C2C12 cell line required puromycin (1.5 μg/ml) in the culture medium. Most experiments on human myotubes were performed with primary human muscle cells isolated from healthy probands and from patients with LGMD2B: DYSF c.855+1delG and c.895G>A; p.G299R; homozygosity for DYSF c.4022T>C; p.L1341P. Muscle specimens were placed in 30.2 mM HEPES containing 130 mM NaCl, 3 mM KCl, 10 mM D-Glucose and subsequently digested in 254 U/ml Collagenase CLS II (Biochrom AG, Berlin, Germany), 100 U/ml Dispase II (Roche, Grenzach-Wyhlen, Germany) supplemented with 10% fetal bovine serum grown in skeletal muscle cell growth medium (Promocell, Heidelberg, Germany) supplemented with 10% fetal bovine serum (Lonza, Cologne, Germany), 2.72 mM glutamine (GlutaMAXTM), 130 mM NaCl, 3 mM KCl, 10 mM D-Glucose and subsequently digested in 254 U/ml Collagenase CLS II (Biochrom AG, Berlin, Germany), 100 U/ml Dispase II (Roche, Grenzach-Wyhlen, Germany) and trypsin/EDTA at 37°C for 45 minutes. Cells were grown in skeletal muscle cell growth medium (Promocell, Heidelberg, Germany) supplemented with 10% fetal bovine serum (Lonza, Cologne, Germany), 2.72 mM glutamine (GlutaMAX™) and gentamicin (400 μg/ml) (Gibco, Paisley, UK). Myoblasts were purified using anti-CD56 ab-coated magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany). Differentiation into myotubes was induced in DMEM containing 2% horse serum (Lonza, Basel, Switzerland) [51]. Dysferlin-deficient C2C12 cell line was a gift from Dr. Robert Brown (University of Massachusetts School of Medicine, Worcester, USA) [51].

Life Cell Imaging

For live cell imaging myoblasts were seeded in 8 well glass slide (Lab-Tek® Chamber Slide™ Coverglass Systems Nunc, Rochester, New York, United States) and were incubated in fusion media for seven days. To identify myotubes cells were stained with anti-NCAM ab (Miltenyi Biotec, Bergisch Gladbach, Germany). For imaging cells were placed in uncoulored DMEM (Gibco, Paisley, UK) and incubated at 37°C and 5% CO2 (heating unit, CO2 controller and tempcontrol 37-2 from PECON, Erbach, Germany). Immediately prior to imaging ATTO-495-labeled TAT-labeled specific peptide was added at a final concentration of 10 μM. The dysferlin-peptide distribution within myotubes was observed for 14 hours.

Laser Wounding Assay

Laser wounding was performed on cultured myotubes as described [35,36] with slight modifications. Briefly, before laser wounding medium was switched to Tyrode solution (140 mM NaCl, 5 mM KCl, 2 mM MgCl2 and 10 mM HEPES, pH 7.2) with 2.5 μM FM 1-43 (Molecular Probes, Invitrogen, Paisley, UK) and 2.5 mM CaCl2. Myotubes were wounded by irradiating a 2.5×2.5 μm boundary area of the plasma membrane at 50% maximum power (30-mW argon-laser) for 37 seconds using a Zeiss LSM 510 META confocal microscope with a 63× oil immersion lens. Images were captured using the Zeiss LSM Image Browser software. In an area of 10×10 μm directly adjacent to the injury site the changes of fluorescence intensity were calculated with ImageJ.

Interventional Atomic Force Microscopy

Myotubes were also wounded by interventional atomic force microscopy. These experiments were performed using the Atomic Force Microscope (AFM) NanoWizard II (JPK Instruments, Berlin, Germany) at 37°C with a silicon cantilever (model C50-T37 from Mikromasch, Tallinn, Estonia) with a spring constant of 0.3 N/m. In all experiments 2 μm longitudinal lesions were set with a force set to 40 nN. Videos were obtained with a 40× objective lens using the ProRes CF microscope camera (Jenoptik, Jena, Germany).

Protein-protein Interaction

The sequence encoding for the C2E domain of DYSF p.L1341P mutation was obtained using the USAF software (Leica) or the Zeiss LSM ZEN software 2010 (Carl Zeiss). Images were assembled using Photoshop CS4 (64-bit).

Immunofluorescence and Western Blotting

HAMLET anti-dysferlin monoclonal antibody (ab) was purchased from Novacat (Newcastle Upon Tyne, UK). Monovalent mouse anti-calnexin ab was acquired from Acris (Hiddenhauen, Germany). Texas red pre-labeled WGA (EY Laboratories, San Mateo, CA, USA) was used as marker for the basal lamina. Nuclei were stained using Hoechst 33342 (Invitrogen). Monoclonal mouse anti-βIβ/GRP78 antibody was obtained from BD Biosciences (Heidelberg, Germany). Rabbit polyclonal antibody against tubulin served as a loading control (Abcam, Cambridge UK). Immunofluorescence and Western blotting were performed according to standard protocols. Protein bands were quantified by Adobe Photoshop CS4. Immunofluorescence images were collected using the Leica DMi6000 (Leica Microsystems, Wetzlar, Germany) or the Zeiss LSM 700 confocal microscope (Carl Zeiss Microscopy GmbH, Germany). Protein-binding studies were performed by surface plasmon resonance analysis (Biacore 2000 with CM5 sensor chip; GE Healthcare Europe, Freiburg, Germany).

Functional Recovery of Missense Mutated Dysferlin

...
RNA Extraction from Cells and cDNA Synthesis from Total RNA

Total RNA was isolated according to the NucleoSpin® RNA II kit from Macherey-Nagel (Duren, Germany). 5–10 g total RNA of each sample was mixed with 3 μl random hexamers (50 ng/μl). DEPC-treated water was added up to the final volume of 12 μl. Each sample was incubated at 70°C for 10 min for primer hybridisation and chilled on ice for at least 1 min. Samples were briefly centrifuged and 8 μl of the reaction mix, containing 4 μl 5 x first strand buffer (Gibco), 2 μl dTTP (0.1 M), 1 μl dNTP mix (10 mM), 1 μl RNase inhibitor (RNasin 40 U), were added. Contents of the tubes were mixed and incubated at 25°C for 5 min. 1 μl (200 U) of Superscript II RT was added before incubating the samples at 42°C for 50 min. cDNA synthesis reaction samples containing random hexamers were first incubated at 25°C for 10 min, followed by 50 min at 42°C. The reaction was inactivated by incubating at 70°C for 15 min and the cDNA was stored at −20°C.

Quantitative Real-time PCR (qRT-PCR)

To detect and quantify (as absolute number of copies or relative amount when normalized to DNA input or additional normalizing genes), we performed a qRT-PCR.

Total cellular RNA was reverse transcribed into DNA. By using specific primer and FAM-TAMRA labeled probes (Table S1) in a TaqMan® PCR we analysed the expression levels of genes compared to the housekeeping gene abl. The qPCR was performed in an Eppendorf realplex2 Mastercycler epgradient S instrument (Eppendorf, Hamburg, Germany). 5 μl of TaqMan® Gene Expression Master Mix (Applied Biosystems, Darmstadt, Germany), 0.25 μl of forward and reverse primer, 0.3 μl of the probe, and 0.2 μl H2O was added to 5 μl of the cDNA or 5 μl of the cDNA standard. All samples were measured in triplicates. Primer and probes for RT-PCR (TaqMan) analysis were ordered from Tib Molbiol as complete gene expression assay or synthesized by BioTez GmbH (Berlin, Germany) (Table S1). Results were normalized to the housekeeping gene abl and analyzed by the ΔΔCt method to give fold induction as compared with untreated control samples. Statistics were performed using the Mann-Whitney-U-Test by Dr. Andreas Busjahn.

Supporting Information

Figure S1 Position of dysferlin-peptides used for relocation experiments. 10- and 15-mer peptides from the dysferlin sequence were synthesized and coupled to the cell penetrating peptide TAT (YGRKKRRQRRR). Peptides A1–4 and B1–4 (Table 1) represent the amino-acid sequence corresponding to DYSF p.G299R in the C2B (red) and p.L1341P in the C2E domain (green) [53].

Figure S2 Nonsense peptides and peptides A4 and B1 do not relocate mutant dysferlin to the sarclemma. C2C12 cells were transfected with either missense-mutated dysferlin cDNA DYSF p.G299R (upper lane) or p.L1341P (lower lane). Transfected cells were treated with TAT-labeled dysferlin-peptides. Bar: 10 μm.

Figure S3 Relocated dysferlin abuts to the basal lamina. Primary human myotubes carrying the dysferlin missense mutation DYSF p.G299R in [A] and immortalized human myotubes carrying the DYSF p.L1341P mutation in [B] were treated with the dysferlin-peptides. Dysferlin was detected by anti-dysferlin ab (left column). Co-staining with WGA as a marker of the basal lamina was performed (middle column). Merge is shown at the right column. Arrows indicate the sarcolemal reallocation of dysferlin by the 10mer mutant dysferlin-peptides. Bar: 10 μm.

Figure S4 DYSF p.L1341P does not stably bind corresponding dysferlin peptides. Protein binding studies were performed by surface plasmon resonance analysis. As analyte the recombinant C2E domain harboring DYSF p.L1341P expressed in E.coli was used. The kinetics of interaction, the rates of association and dissociation between the C2E and the corresponding peptides B1, B2 and B3 were tested. There is no evidence for binding between C2E and dysferlin peptides.

Figure S5 ER stress is reduced by TAT-labeled dysferlin-peptides. [A] In human myotubes harboring the DYSF p.G299R mutation specific peptides reduce the relative gene expression of the ER stress mediators ATF6 (ATF6), EIF2AK3 (PERK) and DDIT3 (CHOP). The nonsense peptide serves as control. Data represent median ± SEM, n = 9/group. P values are listed in [C]. [B] The 15mer mutant peptide A4 also effectively reduces ER stress, whereas both wildtype peptides A1 and A3 do not have an equivalent effect on the relative gene expression of ATF6, EIF2AK3 and DDIT3. Data represent median ± SEM, n = 3/group. [C] Supplementary statistics to Fig. 6 and Fig. S5A. The fold induction of each sample condition (treatment with peptide A2 or nonsense peptide) is compared to untreated controls DYSF p.G299R. Median ± SEM for each condition is listed and p values are indicated in the table; n = 9/group.

Table S1 Primers and probes for RT-PCR.

Video S1 FM1-43 uptake after laser induced damage in DYSF p.G299R primary human myotubes. No peptides added.

Video S2 FM1-43 uptake after laser induced damage in DYSF p.G299R primary human myotubes. Nonsense peptide added (control peptide).

Video S3 FM1-43 uptake after laser induced damage in DYSF p.G299R primary human myotubes. Corresponding peptide A2 added.

Video S4 FM1-43 uptake after laser induced damage in normal primary human myotubes.

Video S5 Sarcolemmal injury in normal primary human myotubes induced by atomic force microscopy.

Video S6 Sarcolemmal injury in DYSF p.L1341P primary human myotubes induced by atomic force microscopy. No peptides added.

Video S7 Sarcolemmal injury in DYSF p.L1341P primary human myotubes induced by atomic force microscopy. Corresponding peptide B2 added.
Video S8  Life cell imaging. ATTO-495-ME-labeled and TAT conjugated dysferlin-peptide B2 in DYSF p.L1341P primary human myotubes. Time lapse is indicated in the video. (MOV)

Acknowledgments

We thank Stephanie Meyer for technical support. We thank Dr. Rachel Owen from JPK for her continuous support in establishing the new AFM application. We thank Dr. Robert Brown for providing us the dysferlin-deficient C2C12 cells as well as Dr. Steven Laval for the GFP-tagged DNF-vector. We thank Dr. Friedrich C. Luft for helpful discussion.

Author Contributions

Conceived and designed the experiments: SS PTD VS. Performed the experiments: VS AM TO UZ RSC SK. Analyzed the data: VS AM TO SS UZ PTD RSC SK. Wrote the paper: VS AM SS.

References

1. Anderson LV, Davison K, Moss JA, Young C, Cullen MJ, et al. (1999) Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet 8: 853–861.
2. Bansal D, Miyake K, Vogel SS, Grosh S, Chen CC, et al. (2003) Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423: 168–172.
3. Bashir R, Britton S, Strachan T, Keers S, Vafiadaki E, et al. (1998) A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in nematode muscular dystrophy type 2B. Nat Genet 20: 37–42.
4. Liu J, Askli M, Illa I, Wu C, Fardeau M, et al. (1998) Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 20: 31–36.
5. Keogh C, Berroud C, Labelle V, Nguyen K, Bernard R, et al. (2009) Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum Mutat 30: E345–E375.
6. Wenzel K, Carl M, Perrot A, Zabojszcza J, Assadi M, et al. (2006) Novel sequence variants in dysferlin-deficient muscular dystrophy leading to mRNA decay and possible C2-domain misfolding. Hum Mutat 27: 599–600.
7. Fujita E, Kouroukis Y, Isao A, Kumanagi H, Misutani A, et al. (2007) Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy (ATGG5a). Hum Mol Genet 16:418–429.
8. Spuler S, Carl M, Zabojsza J, Strazh V, Busbly K, et al. (2008) Dysferlin-deficient muscular dystrophy features amyloidosis. Ann Neurol 63: 323–328.
9. Eveson TJ, Peat RA, Lea A, Britol F, Lo HP, et al. (2010) Reduced plasma membrane expression of dysferlin mutants is attributed to accelerated endocytosis via a syntaxin-9-associated pathway. J Biol Chem 285: 28535–28539.
10. Bartolini M, Andrisano V (2010) Strategies for the inhibition of protein aggregation by small-molecule proteostasis regulators for protein conformational diseases. Nat Chem 2: 553–561.
11. Jones D (2010) Modifying protein misfolding. Nat Rev Drug Discov 9: 825–827.
12. Ushioda R, Hoseki J, Araki K, Jansen G, Thomas DY, et al. (2008) ERdj5 is a plasma membrane protein and is expressed early in human development. J Biol Chem 267: 16751–16754.
13. Anderson LV, Davison K, Moss JA, Young C, Cullen MJ, et al. (1999) Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet 8: 853–861.
14. Ron D, Habener JF (1992) CHOP, a novel developmentally regulated nuclear protein that dimers with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev 6: 439–453.
15. Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, et al. (1998) CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 12: 982–995.
16. Kozutsumi Y, Segal M, Normington K, Gething MJ, Sambrook J (1988) The presence of malfolded proteins in the endoplasmic reticulum signals the stress induction of glucose regulated proteins and blocks secretion of selective membrane proteins and microfilaments using atomic force microscopy. Exp Mol Med 42: 597–605.
17. Kuri K, Wang N, Yu MF (2010) Nanonectin: a multifunctional tool for biological studies in living cells. Nanoscale 2: 363–372.
18. Calamini B, Silva MC, Madoux F, Hurt MM, Khanna S, et al. (2012) Small-molecule proteostasis regulators for protein conformational diseases. Nat Chem Biol 8: 185–196.
19. Cortex-Boyeka E, Hong JS, Berdiev BK, Formenterra JA, Renzullo J, et al. (2009) A truncated CFTR protein rescues endogenous DeltaF508-CFTR and corrects chloride transport in mice. Proc Natl Acad Sci U S A 106: 9221–9226.
20. Xu L, Pallikathu S, Hou Z, Migney GA, Roblia SL, et al. (2011) Dysferlin forms a mediator c2 domains and the transmembrane domain in vitro and in living cells. PLoS One 6: e22764.
21. Lestal Y, Bartoli M, Bourg N, Koulaouz C, Bentahila A, et al. (2010) Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum Mol Genet 19: 1389–13902.
22. Ling YH, Liebes L, Ng B, Buckley M, Elliott PJ, et al. (2002) PS-341, a novel activator of Nrf2 that protects against neurodegenerative disease. Science 298: 569–572.
23. Ushioda R, Hoseki J, Araki K, Jansen G, Thomas DY, et al. (2008) ERdj5 is a plasma membrane protein and is expressed early in human development. J Biol Chem 267: 16751–16754.
24. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, et al. (2010) Strumpellin is a novel valosin-containing protein binding partner linking hereditary spastic paraplegia to protein aggregation diseases. Brain 133: 2920–2941.
25. Fukai T (2007) Targeting proteasome worsens atherosclerosis. Circ Res 101: 859–861.
48. Herrmann J, Saguner AM, Versari D, Peterson TE, Chade A, et al. (2007) Chronic proteasome inhibition contributes to coronary atherosclerosis. Circ Res 101: 865–874.

49. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609–2617.

50. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, et al. (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24: 3113–3120.

51. Belanto JJ, Diaz-Perez SV, Magyar CE, Maxwell MM, Yilmaz Y, et al. (2010) Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation. Neuromuscul Disord 20: 111–121.

52. Philipp S, Bigot A, Marg A, Moul Y, Spuler S, et al. (2012) Dysferlin-deficient immortalized human myoblasts and myotubes as a useful tool to study dysferlinopathy. PLoS Currents Muscular Dystrophy. 2012 Feb 28 [last modified: 2012 Mar 26] doi: 10.1371/currents.RRN1298.

53. Anderson LV, Harrison RM, Pogue R, Vafiadaki E, Pollitt C, et al. (2000) Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscul Disord 10: 553–559.